AU781175B2 - Recombinant toxin A/toxin B vaccine against Clostridium Difficile - Google Patents
Recombinant toxin A/toxin B vaccine against Clostridium Difficile Download PDFInfo
- Publication number
- AU781175B2 AU781175B2 AU49732/00A AU4973200A AU781175B2 AU 781175 B2 AU781175 B2 AU 781175B2 AU 49732/00 A AU49732/00 A AU 49732/00A AU 4973200 A AU4973200 A AU 4973200A AU 781175 B2 AU781175 B2 AU 781175B2
- Authority
- AU
- Australia
- Prior art keywords
- toxin
- raru
- composition
- rbru
- protein component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101710084578 Short neurotoxin 1 Proteins 0.000 title claims description 46
- 101710182532 Toxin a Proteins 0.000 title claims description 46
- 241000193163 Clostridioides difficile Species 0.000 title claims description 36
- 101710182223 Toxin B Proteins 0.000 title claims description 30
- 229960005486 vaccine Drugs 0.000 title description 14
- 239000012634 fragment Substances 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 48
- 230000002163 immunogen Effects 0.000 claims description 47
- 235000004252 protein component Nutrition 0.000 claims description 28
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 25
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- 230000003472 neutralizing effect Effects 0.000 claims description 12
- 229930027917 kanamycin Natural products 0.000 claims description 10
- 229960000318 kanamycin Drugs 0.000 claims description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 10
- 229930182823 kanamycin A Natural products 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 241000371652 Curvularia clavata Species 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 61
- 108700012359 toxins Proteins 0.000 description 28
- 239000003053 toxin Substances 0.000 description 27
- 231100000765 toxin Toxicity 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 239000013604 expression vector Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 3
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241001112695 Clostridiales Species 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 102000000340 Glucosyltransferases Human genes 0.000 description 2
- 108010055629 Glucosyltransferases Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108700022831 Clostridium difficile toxB Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150039863 Rich gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- IXEVGHXRXDBAOB-BREBYQMCSA-N [(1r,3r,4r)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-thiocyanatoacetate Chemical compound C1C[C@@]2(C)[C@H](OC(=O)CSC#N)C[C@@H]1C2(C)C IXEVGHXRXDBAOB-BREBYQMCSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 101150118347 kn gene Proteins 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- -1 type 2 core carbohydrate Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12868699P | 1999-04-09 | 1999-04-09 | |
| US60/128686 | 1999-04-09 | ||
| US18620100P | 2000-03-01 | 2000-03-01 | |
| US60/186201 | 2000-03-01 | ||
| US19011100P | 2000-03-20 | 2000-03-20 | |
| US60/190111 | 2000-03-20 | ||
| PCT/US2000/009525 WO2000061762A1 (en) | 1999-04-09 | 2000-04-10 | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4973200A AU4973200A (en) | 2000-11-14 |
| AU781175B2 true AU781175B2 (en) | 2005-05-12 |
Family
ID=27383767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU49732/00A Ceased AU781175B2 (en) | 1999-04-09 | 2000-04-10 | Recombinant toxin A/toxin B vaccine against Clostridium Difficile |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1169456B1 (https=) |
| JP (2) | JP2002542169A (https=) |
| AU (1) | AU781175B2 (https=) |
| CA (1) | CA2365915C (https=) |
| WO (1) | WO2000061762A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205206D0 (en) * | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| US6912151B2 (en) | 2002-06-28 | 2005-06-28 | Synopsys, Inc. | Negative differential resistance (NDR) based memory device with reduced body effects |
| UA105508C2 (uk) * | 2008-12-03 | 2014-05-26 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Спосіб одержання вакцини проти clostridium difficile |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| AU2016203241B2 (en) * | 2011-05-27 | 2018-05-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| HUE037126T2 (hu) | 2011-05-27 | 2018-08-28 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| WO2013084071A2 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014086787A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| ES2750525T3 (es) | 2012-12-27 | 2020-03-26 | Glaxosmithkline Biologicals Sa | Procedimientos y composiciones relacionados con CRM197 |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| US12076352B2 (en) | 2018-06-19 | 2024-09-03 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN113329766A (zh) * | 2018-11-16 | 2021-08-31 | 马特里瓦克斯公司 | 艰难梭菌多组分疫苗 |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| CN112442472B (zh) * | 2020-11-30 | 2023-05-26 | 四川大学华西医院 | 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| EP4658302A1 (en) | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996012802A1 (en) * | 1989-10-31 | 1996-05-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| WO1997002836A1 (en) * | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Clostridium difficile toxins as mucosal adjuvants |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US4530833A (en) | 1982-09-13 | 1985-07-23 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4533630A (en) | 1982-09-13 | 1985-08-06 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4863852A (en) | 1985-07-03 | 1989-09-05 | Virginia Tech Intellectual Properties, Inc. | Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors |
| GB8517071D0 (en) * | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5098826A (en) | 1990-03-09 | 1992-03-24 | Virginia Tech Intellectual Properties, Inc. | Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors |
| US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| JPH09323999A (ja) * | 1996-06-03 | 1997-12-16 | Unitika Ltd | 人工タンパク質ポリマー |
| EP1000155A1 (en) * | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| PL2753352T5 (pl) * | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
-
2000
- 2000-04-10 JP JP2000611685A patent/JP2002542169A/ja active Pending
- 2000-04-10 EP EP00931926A patent/EP1169456B1/en not_active Expired - Lifetime
- 2000-04-10 WO PCT/US2000/009525 patent/WO2000061762A1/en not_active Ceased
- 2000-04-10 CA CA2365915A patent/CA2365915C/en not_active Expired - Fee Related
- 2000-04-10 EP EP12155470A patent/EP2502998A3/en not_active Withdrawn
- 2000-04-10 AU AU49732/00A patent/AU781175B2/en not_active Ceased
-
2009
- 2009-12-28 JP JP2009298925A patent/JP5566684B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996012802A1 (en) * | 1989-10-31 | 1996-05-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| WO1997002836A1 (en) * | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Clostridium difficile toxins as mucosal adjuvants |
Non-Patent Citations (1)
| Title |
|---|
| DOVE ET AL; INFECT IMMUN, 1990, VOL 88, P 480-488 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2502998A3 (en) | 2013-02-27 |
| CA2365915A1 (en) | 2000-10-19 |
| JP2010083898A (ja) | 2010-04-15 |
| JP2002542169A (ja) | 2002-12-10 |
| WO2000061762A1 (en) | 2000-10-19 |
| AU4973200A (en) | 2000-11-14 |
| EP1169456A1 (en) | 2002-01-09 |
| EP2502998A2 (en) | 2012-09-26 |
| JP5566684B2 (ja) | 2014-08-06 |
| EP1169456B1 (en) | 2012-07-11 |
| CA2365915C (en) | 2015-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5566684B2 (ja) | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン | |
| AU781027B2 (en) | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines | |
| US6939548B2 (en) | Methods to produce high levels of C. difficile toxins | |
| JP4091112B2 (ja) | リポタンパク質の発現 | |
| EP0453024B1 (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
| US5888810A (en) | Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein | |
| JP6329544B2 (ja) | 新規生弱毒化赤痢菌属（Ｓｈｉｇｅｌｌａ）ワクチン | |
| Häse et al. | Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs | |
| NZ258684A (en) | Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen | |
| HUT64596A (en) | Recombinant vaccine against swine pleuropneumonie | |
| RU2140981C1 (ru) | Авирулентный штамм vibrio cholerae не-01 серогруппы (варианты), способ получения штамма (варианты), вакцина | |
| WO1998023763A1 (en) | Heterologous antigens in live cell v. cholerae strains | |
| AU644828B2 (en) | Novel vaccine | |
| US6602507B1 (en) | Synthetic peptides from streptococcal M protein and vaccines prepared therefrom | |
| JP2004529601A (ja) | 組換えインフルエンザ菌アドヘシンタンパク質 | |
| DE69325294T2 (de) | Keuchhusten-Impfstoff | |
| JP3654512B2 (ja) | 防御組換えｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ（インフルエンザ菌）高分子量タンパク質をコードする核酸分子、形質転換ベクター、形質転換菌株ならびにそれらを用いたタンパク質の生産方法 | |
| Cho et al. | Active Immunity and Passive Protective Antibody against Pseudomonas Exotoxin A Intoxication | |
| MXPA01003571A (en) | Protective recombinant haemophilus influenzae |